Shobhit Seth

Shobhit Seth is a freelance financial writer, derivatives trader and consultant specializing in derivatives pricing and quantitative research. His career spans over 14 years as a Product Manager (Derivatives, Financial Data & Risk Management) at leading financial services companies across the UK, Europe, US and India. He has written extensively on topics pertaining to Derivatives Pricing, Derivatives Combinations & Structures, and Derivatives Trading Strategies. A lot of his work is available at www.FuturesOptionsETC.com, a site on Derivatives Trading which Shobhit owns and maintains. Shobhit also has expertise in index based products and ETFs, and he conducts training sessions on derivatives and related financial topics.

Shobhit has a Master’s degree in Financial Management (Specialization in Derivatives & Quantitative Research) from the Netherlands and a Bachelor of Technology degree (Electronics & Communications Engineering) from India.

  • Showing 1-15 of 1,025 items
  • 1
  • 2
  • 3
  • ...
  • 69
  • >>
  1. Stocks

    FDA Rejects Amphastar Opioid Overdose Drug (AMPH)

    FDA has issued a CRL for Amphastar’s nasal spray version of opioid-overdose therapy Naloxone Hydrochloride
  2. Stocks

    Trevena Plunges 34% On Painkiller Results (TRVN)

    Trevena’s painkiller oliceridine beat a placebo, but faltered against morphine in a clinical study.
  3. Stocks

    Philips Monitoring System Gets FDA Clearance (PHG)

    Philips got FDA clearance for an in-patient continuous monitoring system.
  4. Stocks

    Sarepta Sells Priority Review Voucher for $125M (SRPT)

    Sarepta sold its Priority Review Voucher for $125 million to Gilead.
  5. Stocks

    BrainStorm Seeks ALS Drug Nod In Canada (BCLI)

    BrainStorm is seeking early approval in Canada for its ALS drug.
  6. Stocks

    Roche Lung Cancer Drug Alecensa Gets EU Nod (RHHBY)

    Roche’s Alecensa adds the large EU market for non-small cell lung cancer treatment.
  7. Stocks

    Momenta's Supply Partner Gets FDA Warning (MNTA)

    The warning will delay FDA approval of Momenta's 40-mg multiple sclerosis drug Glatopa.
  8. Stocks

    ArQule Liver Cancer Drug Fails Phase 3 (ARQL)

    ArQule’s liver cancer drug ARQ 197 failed a late-stage clinical trial.
  9. Stocks

    Roche Sues Amgen Over Avastin Biosimilar (AMGN)

    Roche filed suit to fend off competition from Amgen’s biosimilar for its bestselling drug Avastin.
  10. Stocks

    Alexion Shelves Rare-Disease Drug SBC-103 (ALXN)

    Alexion has shelved its mucopolysaccharidosis drug SBC-103, which it acquired in 2015.
  11. Stocks

    Gilead Sells Anti-Addiction Drug to Amygdala (GILD)

    Gilead sold its GS-6637 drug and alcohol addiction medicine to Amygdala.
  12. Stocks

    ImmunoGen's 4Q Loss Wider Than Expected (IMGN)

    ImmunoGen failed to meet analysts' revenue and earnings estimates for the fourth quarter.
  13. Stocks

    Celgene MS Drug Reports Positive Phase 3 Data (CELG)

    Celgene’s multiple sclerosis drug ozanimod beat rival Avonex in a Phase 3 study.
  14. Stocks

    Ziopharm 4Q Loss 11 Cents a Share (ZIOP)

    Ziopharm's fourth quarter loss was in line with analyst estimates.
  15. Stocks

    Court Rules Against Berkeley In CRISPR Patent Case (CRSP)

    UC Berkeley suffered a major setback in CRISPR patent infringement lawsuit against MIT and Harvard.
  • Showing 1-15 of 1,025 items
  • 1
  • 2
  • 3
  • ...
  • 69
  • >>